186 related articles for article (PubMed ID: 34696358)
1. Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.
Barh D; Tiwari S; Gabriel Rodrigues Gomes L; Weener ME; Alzahrani KJ; Alsharif KF; Aljabali AAA; Tambuwala MM; Lundstrom K; Hassan SS; Serrano-Aroca Á; Takayama K; Ghosh P; Redwan EM; Silva Andrade B; Soares SC; Azevedo V; Uversky VN
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696358
[TBL] [Abstract][Full Text] [Related]
2. ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation.
Miao G; Zhao H; Li Y; Ji M; Chen Y; Shi Y; Bi Y; Wang P; Zhang H
Dev Cell; 2021 Feb; 56(4):427-442.e5. PubMed ID: 33422265
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein.
Tan TH; Patton E; Munro CA; Corzo-Leon DE; Porter AJ; Palliyil S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835009
[TBL] [Abstract][Full Text] [Related]
4. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
5. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
6. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
F1000Res; 2020; 9():576. PubMed ID: 32802318
[No Abstract] [Full Text] [Related]
7. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 ORF3a positively regulates NF-κB activity by enhancing IKKβ-NEMO interaction.
Nie Y; Mou L; Long Q; Deng D; Hu R; Cheng J; Wu J
Virus Res; 2023 Apr; 328():199086. PubMed ID: 36894068
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.
Bell BN; Powell AE; Rodriguez C; Cochran JR; Kim PS
Protein Sci; 2021 Apr; 30(4):716-727. PubMed ID: 33586288
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.
Gowda P; Patrick S; Joshi SD; Kumawat RK; Sen E
Cytokine; 2021 Jun; 142():155496. PubMed ID: 33773396
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 ORF3a-Mediated NF-κB Activation Is Not Dependent on TRAF-Binding Sequence.
Busscher BM; Befekadu HB; Liu Z; Xiao TS
Viruses; 2023 Nov; 15(11):. PubMed ID: 38005906
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
Fu D; Zhang G; Wang Y; Zhang Z; Hu H; Shen S; Wu J; Li B; Li X; Fang Y; Liu J; Wang Q; Zhou Y; Wang W; Li Y; Lu Z; Wang X; Nie C; Tian Y; Chen D; Wang Y; Zhou X; Wang Q; Yu F; Zhang C; Deng C; Zhou L; Guan G; Shao N; Lou Z; Deng F; Zhang H; Chen X; Wang M; Liu L; Rao Z; Guo Y
PLoS Biol; 2021 May; 19(5):e3001209. PubMed ID: 33961621
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
15. NMR Based SARS-CoV-2 Antibody Screening.
Schoenle MV; Li Y; Yuan M; Clarkson MW; Wilson IA; Peti W; Page R
J Am Chem Soc; 2021 Jun; 143(21):7930-7934. PubMed ID: 34018723
[TBL] [Abstract][Full Text] [Related]
16. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress.
Chen D; Zheng Q; Sun L; Ji M; Li Y; Deng H; Zhang H
Dev Cell; 2021 Dec; 56(23):3250-3263.e5. PubMed ID: 34706264
[TBL] [Abstract][Full Text] [Related]
17. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V.
Bollavaram K; Leeman TH; Lee MW; Kulkarni A; Upshaw SG; Yang J; Song H; Platt MO
Protein Sci; 2021 Jun; 30(6):1131-1143. PubMed ID: 33786919
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell.
Puray-Chavez M; LaPak KM; Schrank TP; Elliott JL; Bhatt DP; Agajanian MJ; Jasuja R; Lawson DQ; Davis K; Rothlauf PW; Liu Z; Jo H; Lee N; Tenneti K; Eschbach JE; Shema Mugisha C; Cousins EM; Cloer EW; Vuong HR; VanBlargan LA; Bailey AL; Gilchuk P; Crowe JE; Diamond MS; Hayes DN; Whelan SPJ; Horani A; Brody SL; Goldfarb D; Major MB; Kutluay SB
Cell Rep; 2021 Jul; 36(2):109364. PubMed ID: 34214467
[TBL] [Abstract][Full Text] [Related]
19. Stereotypic neutralizing V
Kim SI; Noh J; Kim S; Choi Y; Yoo DK; Lee Y; Lee H; Jung J; Kang CK; Song KH; Choe PG; Kim HB; Kim ES; Kim NJ; Seong MW; Park WB; Oh MD; Kwon S; Chung J
Sci Transl Med; 2021 Jan; 13(578):. PubMed ID: 33397677
[TBL] [Abstract][Full Text] [Related]
20. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
